MDM2 and chronic myelogenous leukemia, BCR-ABL1 positive: Secondly, they also identify multiple novel candidate agents, e.g., MDM2, WEE1 inhibitors, and Mepacrine, as selective agents depleting CML-LSCs through mechanisms separate from TKIs.